Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2022 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
October 06, 2022 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

Autologous TIL therapy enhanced with Lyell’s Epi-R™ reprogramming technology designed to create polyclonal T cell populations with properties of durable stemness and improved functionPhase 1 trial to...
October 05, 2022 08:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Five poster presentations to include preclinical data describing new T-cell reprogramming technology being incorporated in LYL119, Lyell’s next product candidate SOUTH SAN FRANCISCO, Calif., Oct. ...
September 28, 2022 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
September 12, 2022 03:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
August 30, 2022 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies...
August 04, 2022 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights

Cash, cash equivalents and marketable securities of $787.0 million as of June 30, 2022 provides funding into 2025 and supports advancement of multiple product candidates through key clinical...
June 07, 2022 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies...
May 10, 2022 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights

Cash, cash equivalents and marketable securities of $838 million as of March 31, 2022 supports advancing a robust cell therapy pipelineResearch highlighting novel reprogramming technologies designed...
May 04, 2022 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid...